• 제목/요약/키워드: maintenance dose

검색결과 169건 처리시간 0.027초

Verification of Mechanical Leaf Gap Error and VMAT Dose Distribution on Varian VitalBeamTM Linear Accelerator

  • Kim, Myeong Soo;Choi, Chang Heon;An, Hyun Joon;Son, Jae Man;Park, So-Yeon
    • 한국의학물리학회지:의학물리
    • /
    • 제29권2호
    • /
    • pp.66-72
    • /
    • 2018
  • The proper position of a multi-leaf collimator (MLC) is essential for the quality of intensity-modulated radiation therapy (IMRT) and volumetric modulated arc radiotherapy (VMAT) dose delivery. Task Group (TG) 142 provides a quality assurance (QA) procedure for MLC position. Our study investigated the QA validation of the mechanical leaf gap measurement and the maintenance procedure. Two $VitalBeam^{TM}$ systems were evaluated to validate the acceptance of an MLC position. The dosimetric leaf gaps (DLGs) were measured for 6 MV, 6 MVFFF, 10 MV, and 15 MV photon beams. A solid water phantom was irradiated using $10{\times}10cm^2$ field size at source-to-surface distance (SSD) of 90 cm and depth of 10 cm. The portal dose image prediction (PDIP) calculation was implemented on a treatment planning system (TPS) called $Eclipse^{TM}$. A total of 20 VMAT plans were used to confirm the accuracy of dose distribution measured by an electronic portal imaging device (EPID) and those predicted by VMAT plans. The measured leaf gaps were 0.30 mm and 0.35 mm for VitalBeam 1 and 2, respectively. The DLG values decreased by an average of 6.9% and 5.9% after mechanical MLC adjustment. Although the passing rates increased slightly, by 1.5% (relative) and 1.2% (absolute) in arc 1, the average passing rates were still within the good dose delivery level (>95%). Our study shows the existence of a mechanical leaf gap error caused by a degenerated MLC motor. This can be recovered by reinitialization of MLC position on the machine control panel. Consequently, the QA procedure should be performed regularly to protect the MLC system.

망간모래여과를 이용한 강변여과수의 망간제거 (Manganese Removal of Bank Filtrate using Manganese Sand Filtration)

  • 김충환;김학철;김한승;김범수;안효원
    • 한국물환경학회지
    • /
    • 제20권5호
    • /
    • pp.409-414
    • /
    • 2004
  • Pilot-scale experiments were performed for the treatment of bank filtrate contammg high manganese concentration around 2mg/L using rapid manganese sand filtration to investigate effects of oxidant dose and pH control on the removal efficiency of manganese. For theoretical dose ranges of oxidant (sodium hypochlorite) between 3 and 4mg/L, the manganese concentration of effluent was 0.57 mg/L, which corresponded to 72.5% removal and was higher than drinking water quality standards of 0.3mg/L. For excess dose ranges of oxidant between 4 and 8mg/L, the manganese concentration of effluent was reduced to 0.14mg/L, which corresponded to 94.5% removal, but the residual chlorine concentration was over 1.0mg/L. On the other hand, manganese removal efficiency drastically increased up to the value of 98.0%, which is equivalent to the effluent concentration of 0.03mg/L by controling pH to the range between 7 and 8 for the theoretical dose of oxidant. Consequently, these results indicated that appropriate dose of chemicals, such as oxidant and alkali, and continuous monitoring of manganese should be necessary to obtain efficient removal of manganese and to optimize the maintenance of treatment facilities for the treatment of bank filtrate with high concentration of manganese.

비만 환자에서 리라글루티드 증량 과정에서 발생한 급성 신손상 (Acute Kidney Injury after Dose-Titration of Liraglutide in an Obese Patient)

  • 이희진;박혜순
    • 비만대사연구학술지
    • /
    • 제1권2호
    • /
    • pp.78-82
    • /
    • 2022
  • Liraglutide (SaxendaR) is prescribed to induce and sustain weight loss in obese patients. The starting dose of liraglutide is 0.6 mg/day for 1 week, which is increased by 0.6 mg/day every week until the full maintenance dose of 3 mg/day is achieved. Such dose titration is needed to prevent side effects, which primarily include gastrointestinal problems such as nausea, diarrhea, constipation, vomiting, dyspepsia, and abdominal pain. A 35-year-old, reportedly healthy obese man receiving liraglutide treatment for obesity visited the emergency room complaining of generalized weakness and dizziness accompanied by repeated diarrhea and vomiting. He reported over 20 episodes of diarrhea starting the day after liraglutide dose escalation from 1.2 mg/day to 1.8 mg/day. Laboratory findings suggested pre-renal acute kidney injury, including serum creatinine 4.77 mg/dl, blood urea nitrogen (BUN) 37 mg/dl, estimated glomerular filtration rate (eGFR) 15 ml/min/1.73 m2, and Fractional excretion of sodium 0.08. After volume repletion therapy, his renal function recovered to a normal range with laboratory values of creatinine 1.08 mg/dl, BUN 14 mg/dl, and eGFR 88 ml/min/1.73 m2. This case emphasizes the need for caution when prescribing glucagon-like peptide-1 receptor agonists, including liraglutide, given the risk of serious renal impairments induced by volume depletion and dehydration through severe-grade diarrhea and vomiting.

Improved postoperative recovery profile in pediatric oral rehabilitation with low-dose dexmedetomidine as an opioid substitute for general anesthesia: a randomized double-blind clinical trial

  • Naveen, Naik B;Jaiswal, Manoj Kumar;Ganesh, Venkata;Singh, Ajay;Meena, Shyam Charan;Amburu, Vamsidhar;Soni, Shiv Lal
    • Journal of Dental Anesthesia and Pain Medicine
    • /
    • 제22권5호
    • /
    • pp.357-367
    • /
    • 2022
  • Background: Low-dose dexmedetomidine may be a suitable alternative to opioids for pediatric ambulatory procedures under general anesthesia (GA). However, the recovery profile remains unclear. Herein, we aimed to evaluate the effects of low-dose dexmedetomidine on the recovery profile of children. Methods: Seventy-two children undergoing ambulatory oral rehabilitation under GA were randomly and equally distributed into two groups (D and F). Group D received an infusion of dexmedetomidine 0.25 ㎍/kg for 4 min for induction, followed by maintenance of 0.4 ㎍/kg/h. Group F received an infusion of fentanyl 1 ㎍/kg over 4 min for induction, followed by maintenance at 1 ㎍/kg/h. The primary outcome was the extubation time. The secondary outcomes were awakening time, end-tidal sevoflurane (ET-Sevo) requirement, change in hemodynamic parameters, Richmond Agitation-Sedation Scale (RASS), Children's Hospital of Eastern Ontario pain scale (CHEOPS) score, length of PACU stay, and incidence of adverse events. Results: Statistically significant differences were observed in the recovery profile between the groups: the median time for extubation was 3.65 (3.44-6.2) vs. 6.25 (4.21-7) minutes in groups D vs. F (P=0.001), respectively, while the corresponding awakening times were 19 (18.75-21) and 22.5 (22-24) minutes, respectively (P < 0.001). The mean ET-Sevo was low in group D (1.1 vs. 1.2; P < 0.001). The heart rate was significantly low across all time points in group D, without resulting in bradycardia. The median RASS and CHEOPS scores were also significantly lower in group D. No significant differences were observed in the mean arterial pressure, incidence of adverse events, or length of PACU stay. Conclusion: Low-dose dexmedetomidine was more effective than fentanyl as an opioid substitute at providing a better recovery profile in pediatric ambulatory oral rehabilitation under GA. Dexmedetomidine also significantly reduced sevoflurane consumption without causing adverse events or prolonging hospital stay.

원전 불균일 방사선장하에서 유효선량 평가를 위한 복수선량계 알고리즘 적용방안 연구 (A Study on the Application of Two-dosimeter Algorithm to Estimate the Effective Dose in an Inhomogeneous Radiation Field at Korean Nuclear Power Plants)

  • 김희근;공태영
    • Journal of Radiation Protection and Research
    • /
    • 제33권4호
    • /
    • pp.151-160
    • /
    • 2008
  • 국내 원전에서는 과거에 불균일 방사선장이 형성되는 고피폭 방사선작업에 2개의 복수선량계(TLD)를 머리와 기슴에 패용하였으며, 이들 선량계 판독값 중에서 최대값을 유효선량으로 평가함으로써 일정 부분이 과대평가되고 있는 것으로 나타났다. 따라서 이러한 문제점을 개선하고자 국제적인 기관에서 제시된 복수선량계 알고리즘을 대상으로 적절한 알고리즘을 선정하기 위한 현장적용 시험을 실시하였다. 여기에는 캐나다 원전사업자(OPG), 미국표준기술협회(ANSI HPS N13.41), NCRP(55/50), NCRP(70/30), EPRI (NRC), Lakshmanan, Kim(Texas A&M University) 알고리즘 등을 대상으로 하였고, 국내 원전의 계획예방정비기간동안 고피폭이 예상되는 방사선작업을 대상으로 작업종사자에게 3개의 복수선량계를 가슴, 머리, 등에 동시에 패용하였고 판독하였다. 이 시험 결과에 따르면 Lakshmanan 알고리즘을 제외하고 유효선량 평가에서 모든 복수선량계 알고리즘이 거의 유사한 경향을 보이는 것으로 나타났다. 한편 현장적용시험 결과와 이들 알고리즘의 기술적 배경과 방사선작업과정에서의 편의성 등을 종합적으로 고려하여 NCRP(55/50) 알고리즘을 최종적으로 선정하였다. 또한 복수선량계 지급조건은 INPO와 ANSI의 지침을 검토하여 빙사선량율이 1 mSv/hr 이상이면서 인체 특정부위 간의 선량율이 30% 이상차이가 나고 단일 작업에서 2mSv 이상피폭을 받을 것으로 예상될 때 지급하는 것으로 결정하였다.

Increment in vitamin D level and bone mineral accrual in children with vitamin D deficiency

  • Rao, Yashwant Kumar;Midha, Tanu;Singh, Satyajeet;Bajpai, Anurag;Tilak, Amita
    • Clinical and Experimental Pediatrics
    • /
    • 제59권7호
    • /
    • pp.292-297
    • /
    • 2016
  • Purpose: To compare different regimens of vitamin D with respect to its serum increment levels and bone mineral accrual in vitamin D-deficient children. Methods: Children identified as being vitamin D deficient (serum levels<20 ng/mL) were divided into 3 treatment groups by stratified block randomization (group 1, 4,000 IU/day of vitamin D3 plus 50 mg/kg/day calcium for 12 weeks; group 2, 30,000 IU/wk of vitamin D3 plus 50 mg/kg/day calcium for 12 weeks; and group 3, 300,000 IU of vitamin D3 once intramuscularly plus 50 mg/kg/day calcium). After regimen completion, each child received a maintenance dose of 400 IU/day vitamin D3 plus 50 mg/kg/day calcium. Their serum vitamin D level was measured after 3 and 12 months. Total body less head bone mineral concentration (BMC) and total body less head bone mineral density (BMD) were measured after 12 months. Results: The mean increment in serum vitamin D levels from baseline to 3 months was significantly higher in group 3 than in groups 1 and 2, but the levels from 3 to 12 months were almost similar among all 3 groups. There were no significant differences among the 3 groups with respect to percentage increase of BMD and BMC. Conclusion: The injectable form of vitamin D was more efficacious than the oral forms in increasing the serum level to the normal range. All 3 regimens were equally effective in increasing the BMC and BMD. The 400 IU/day maintenance dose was sufficient to keep the serum level within the normal range.

A Pilot Randomized Trial of As-Needed Budesonide-Formoterol for Stepping Down Controller Treatment in Moderate Asthma with Complete Remission

  • Nakwan, Narongwit;Ruklerd, Thidarat;Taptawee, Pattarawadee
    • Tuberculosis and Respiratory Diseases
    • /
    • 제85권3호
    • /
    • pp.227-236
    • /
    • 2022
  • Background: The use of low-dose inhaled corticosteroid-formoterol as reliever monotherapy has recently been recommended in the asthma treatment guidelines. However, the efficacy of this treatment strategy has not yet been determined during the stepping-down period in moderate asthma. This study aimed to evaluate the feasibility of reducing treatment to as-needed budesonide-formoterol (BFM) in moderate asthma with complete remission. Methods: We randomly assigned 31 patients (8 males and 23 females with a mean age of 57.2 years) with complete remission of asthma by inhaled BFM (160/4.5 ㎍) twice daily to receive BFM (160/4.5 ㎍) as needed (16 patients), or budesonide (BUD) (200 ㎍) twice daily (15 patients). The study was an open-label study done for 48 weeks, with the primary outcome as the cumulative percentages of patients with treatment failure (asthma exacerbation or loss of asthma control or lack of satisfaction after using medications) in the two groups. Results: Six patients (42%) using as-needed BFM had treatment failure, as compared with three patients (21.4%) using BUD maintenance (hazards ratio for as-needed BFM, 1.77; 95% confidential interval, 0.44-7.12; p=0.41). The changes in forced expiratory volume in 1 second were -211.3 mL with as-needed BFM versus -97.8 mL with BUD maintenance (difference, 113.5 mL; p=0.75) and the change in fractional exhaled nitric oxide was significantly higher in both groups, at 8.68 parts per billion (ppb) in the as-needed BFM group and 2.5 ppb. in the BUD maintenance group (difference, 6.18 ppb; p=0.049). Conclusion: Compared with BUD maintenance, there were no significant differences in treatment failure rate in patients who received as-needed BFM during the stepping down period in moderate asthma. However, they showed reduced lung function and relapsed airway inflammation. The results are limited by imprecision, and further large RCTs are needed.

양극성장애 입원환자에서 항정신병약물치료와 관련된 임상요인 - 리스페리돈과 전형적 항정신병약물과의 비교를 중심으로 - (Clinical Factors Related with Antipsychotics Treatment in Bipolar Inpatients - Comparison of Risperidone and Classical Antipsychotics -)

  • 임세원;이민수;곽동일;정인과
    • 생물정신의학
    • /
    • 제7권1호
    • /
    • pp.99-106
    • /
    • 2000
  • Background : In spite of relative high risk of extrapyramidal side effect and tardive dyskinesia, it is common clinical practice to use antipyschotics in treatment of bipolar I disorder. But in Korea, there has been few study about clinical factors related with antipsychotics treatment in bipolar disorder patients. So the author studied about the clinical factors related with antipsychotics treatment in bipolar inpatients focusing on the comparison of risperidone and classical antipsychotics. Method : By reviewing medical record retrospectively, datas about patient-related, illness-related, and treatment-related clinical factors on antipsychotics use were collected. Association between antipsychotics dose and duration and clinical factors were analysed by statistical method. Results : Aggressive behavior was only statistically significant factor associated with antipsychotics use. And in the case of aggression, maintenance dose of risperidone was not changed(p=0.84), but dose of classical antipsychotics was increased significantly(p=0.005). Total hospital days and antipsychotics treatment duration showed no difference between risperidone and classical antipsychotics treatment groups. Conclusion : Clinical factors associated with antipsychotics use was aggressive behavior. In the case of aggression, risperidone required lesser dose increment compared with classical antipsychotics.

  • PDF

구내 촬영용 방사선 장치의 촬영조건에 따른 선량변화 분석 (Analysis of Condition Changing on Dose Variation using Intraoral Radiation Devices)

  • 김영재;이용탁;송현철
    • 한국방사선학회논문지
    • /
    • 제6권2호
    • /
    • pp.137-142
    • /
    • 2012
  • 본 연구는 구강 내 방사선 촬영 시 동일조건 하에서 촬영장비의 기종을 다르게 한 경우와 동일 기종에서 노출조건을 일정하게 하였을 경우 획득되는 방사선의 선량변화를 알아보고자 하였다. 장비의 기종에 따른 변화를 알아보기 위해 3대의 각기 다른 촬영 장치를 이용하여 상악 전치부, 소구치부, 대구치부의 3가지의 촬영조건을 이용하여 선량을 측정하였고 장치의 재현성 검사를 위해서 각 장치에 동일한 조건으로 3회 조사하여 선량변화를 알아보았다. 선량의 측정은 반도체 측정기를 사용하였으며, 필름의 농도값을 획득하여 진단에 유효적인 범위에 만족하는지 분석해 보았다. 같은 촬영기를 사용하여 실험한 결과 각 부위별로 선량의 차이는 최대값과 최소값이 적게는 3배 많게는 10배의 선량 차이를 보였다. 흑화도의 범위 또한 적절한 범위인 0.25~2.0를 초과한 2.10~2.95의 허용범위를 보였다. 동일한 촬영기로 특정 부위를 같은 조건에서 촬영하더라도 측정된 선량값은 큰 차이를 보였으며 필름의 농도 분석의 결과 적합한 농도 분포를 보이지 않았던 것으로 나타났다. 이는 환자의 재촬영을 발생시킬 수 있으며 진단시 오류를 일으킬 수 있어 환자의 피폭에 직 간접적인 피해를 일으킬 수 있다. 따라서 치과 방사선 촬영장치 또한 정기점검이 필요할 것으로 생각되며 표준화된 촬영조건과 현상조건이 제공되어야 한다고 사료된다.

Efficacy of 10-Injection Induced Modified Rush Immunotherapy in Dogs with Atopic Dermatitis

  • Kim, Hyun-Tae;Lee, Wang-Hui;Park, Seong-Jun
    • 한국임상수의학회지
    • /
    • 제37권3호
    • /
    • pp.141-144
    • /
    • 2020
  • Modified rush immunotherapy (IT), by combination of rush IT and conventional IT, provides a faster method to reach maintenance dose, leading to higher patient adherence when compared with conventional IT, decreasing systemic adverse reactions when compared with a standard rush IT. Ten atopic dogs of this study include fulfillment of Favrot's criteria. Offending allergens were identified by the use of IDST. During the induction period, the dogs were received a total of 10 injections. Five injections were administrated every 30 minutes in a day with gradually increasing amounts and concentrations of allergens, and the last 5 injections were administered every 3 days. The efficacy of 10-injection induced mRIT was assessed using the canine atopic dermatitis extent and severity index (CADESI). During maintenance period, reduction rate from baseline scores varied between 3.2% and 60.9% and the after 6 months of therapy for CADESI-03 score in 6 of the 10 dogs. Adverse reactions were not observed in these dogs during induction period by mRIT with 10 injections. Based on these results, our modified rush IT protocol is considered to be a useful protocol to treat canine atopic dermatitis.